Alligator Bioscience announced the appointment of Sumeet Ambarkhane, MD, as its Chief Medical Officer. In this role, Sumeet will provide medical leadership and direction in the development of Alligator's best-in-class preclinical and clinical pipeline, including Alligator's lead assets mitazalimab, a CD40 agonist currently in Phase II clinical development, and ATOR-1017, a 4-1BB agonist in Phase I. Sumeet is a seasoned professional with over 20 years of drug development experience in academia and in the biotechnology and pharmaceutical industries. Sumeet has a proven track record of advancing investigational medicines including immunotherapy-biologics, from early phases of development through regulatory approvals and adoption into clinical practice.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.194 SEK | -2.13% |
|
+3.10% | +73.88% |
07-11 | Transcript : Alligator Bioscience AB, Q2 2024 Earnings Call, Jul 11, 2024 | |
07-11 | Alligator Bioscience AB Appoints Johan Giléus as Chief Financial Officer as of August 12, 2024 | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+73.88% | 87.09M | |
+24.52% | 47.96B | |
+1.69% | 42.45B | |
+44.53% | 41.47B | |
+27.97% | 31.6B | |
+21.48% | 28.63B | |
-6.35% | 28.03B | |
+52.47% | 14.56B | |
+48.13% | 14.14B | |
+3.70% | 12.58B |
- Stock Market
- Equities
- ATORX Stock
- News Alligator Bioscience AB
- Alligator Bioscience Appoints Sumeet Ambarkhane as Chief Medical Officer